X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.ema.europa.eu/en/documents/overview/vanflyta-epar-medicine-overview_en.pdf
https://www.onclive.com/view/quizartinib-plus-induction-chemotherapy-provides-survival-benefit-in-flt3-itd-mutated-aml
https://www.onclive.com/view/frontline-quizartinib-plus-chemotherapy-shows-curative-potential-in-flt3-itd-wild-type-aml
https://www.daiichisankyo.com/files/news/pressrelease/pdf/202307/20230720_E.pdf
https://endpts.com/fda-delays-decision-for-daiichi-sankyos-acute-myeloid-leukemia-drug-quizartinib/
https://www.daiichisankyo.com/files/news/pressrelease/pdf/202208/20220830_E.pdf
https://www.fiercebiotech.com/biotech/daiichi-sankyos-survival-data-means-it-may-finally-catch-novartis-astellas-aml-race
https://trialsitenews.com/daiichi-announces-positive-topline-results-from-phase-3-quantum-first-trial-evaluating-quizartinib-in-patients-with-newly-diagnosed-flt3-itd-positive-aml/
https://www.evaluate.com/vantage/articles/news/trial-results/daiichi-could-be-rewarded-persisting-vanflyta
http://www.pmlive.com/pharma_news/daiichi_starts_challenging_astellas_for_japanese_aml_market_1312590
https://endpts.com/astellas-aml-drug-wins-over-chmp-strengthening-lead-on-daiichi-sankyo/
https://www.fiercebiotech.com/biotech/fda-nixes-daiichi-s-blood-cancer-drug-quizartinib-as-japanese-regulators-wave-it-through
https://www.prnewswire.com/news-releases/daiichi-sankyos-vanflyta-receives-approval-in-japan-for-the-treatment-of-relapsedrefractory-flt3-itd-aml-300870240.html
https://www.fiercepharma.com/pharma-asia/fiercepharmaasia-post-shire-takeda-outlook-generics-price-fixing-suit-daiichi-s
https://endpts.com/daiichi-sankyo-disappointed-as-fda-experts-spurn-aml-drug-but-vote-in-favor-of-rare-tumor-drug/
https://www.fiercebiotech.com/biotech/fda-questions-credibility-daiichi-data-ahead-adcomm
https://www.fiercebiotech.com/biotech/daiichi-s-xospata-rival-pushed-back-by-fda-as-it-combs-over-new-data
https://www.prnewswire.com/news-releases/daiichi-sankyo-initiates-first-novel-novel-combination-study-of-two-investigational-agents-within-its-aml-franchise-in-patients-with-aml-300768455.html
https://www.biospectrumasia.com/news/25/11899/daiichi-sankyo-submits-nda-in-japan-for-leukemia-drug.html
https://endpts.com/as-nda-talks-loom-fda-hands-daiichi-sankyo-a-breakthrough-on-its-410m-aml-drug-quizartinib/
Market Place
Share 
